The German pharmaceutical company Grunenthal has announced the start of a human addiction potential (HAP) trial of a first-in-class analgesic called cebranopadol, described as “less addictive” than previous medications. We’ve been down this road before. This medication is both a mu-opioid peptide and nociptin/orphanin FQ peptide (NOP) receptor agonist. I must confess I had to
Novel medications and genetic tests: a perfect storm for physician liability originally appeared in KevinMD.com.
